Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Operating Leases (2022 - 2025)

Coeptis Therapeutics Holdings (COEP) has 4 years of Operating Leases data on record, last reported at $40612.0 in Q2 2025.

  • For Q2 2025, Operating Leases fell 49.7% year-over-year to $40612.0; the TTM value through Jun 2025 reached $40612.0, down 49.7%, while the annual FY2024 figure was $18875.0, 80.98% down from the prior year.
  • Operating Leases reached $40612.0 in Q2 2025 per COEP's latest filing, up from $18874.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $99226.0 in Q4 2023 and bottomed at $14723.0 in Q4 2022.
  • Average Operating Leases over 4 years is $41896.9, with a median of $35999.0 recorded in 2023.
  • Peak YoY movement for Operating Leases: surged 573.95% in 2023, then crashed 80.98% in 2024.
  • A 4-year view of Operating Leases shows it stood at $14723.0 in 2022, then soared by 573.95% to $99226.0 in 2023, then plummeted by 80.98% to $18875.0 in 2024, then surged by 115.16% to $40612.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $40612.0 in Q2 2025, $18874.0 in Q1 2025, and $18875.0 in Q4 2024.